glp 1 triple agonist retatrutide ly3437943 glp-1 gip glucagon mechanism Beyond -1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based Retatrutide Obesity Triple Agonist Targeting
Pay in 4 interest-free payments of $5.14 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11





![Ozempic Lawsuit [July 2026 Update]](https://www.torhoermanlaw.com/wp-content/uploads/2024/05/Health-Problems-Potentially-Linked-to-Ozempic-and-GLP-1-Drugs.jpg)


















